

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehp508@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

Supplemental Material

Per- and Polyfluoroalkyl Substances and Risk of Myocardial Infarction and Stroke: A Nested Case–Control Study in Sweden

Tessa Schillemans, Carolina Donat-Vargas, Christian H. Lindh, Ulf de Faire, Alicja Wolk, Karin Leander, and Agneta Åkesson

Table of Contents

Table S1. Limit of detection (LOD) and between-run precision. Concentrations and coefficient of variation (CV) in three quality control (QC) samples n=31.

Table S2. Between-run precision of two reference samples originating from participation in the HBM4EU program and prepared as quality controls (QC). Concentrations, expected concentrations and coefficient of variation (CV) in n=31 repeated analysis are shown.

Table S3. Baseline (2003-2009 and 1997-1999, respectively) characteristics by myocardial infarction (MI) case-control status of 398 women from the Swedish Mammography Cohort-Clinical and of 422 men and women from the Swedish 60 year-old cohort.

Table S4. Baseline (2003-2009 and 1997-1999, respectively) characteristics by stroke case-control status of 344 women from the Swedish Mammography Cohort-Clinical and of 364 men and women from the Swedish 60 year-old cohort.

Table S5. Multivariable-adjusted cross-sectional associations in controls between baseline PFAS plasma concentrations and total cholesterol, LDL, HDL and triglycerides in 631 men and women from two pooled Swedish cohorts, estimated using linear mixed effects models – PFHpA and PFOA results are from 60YO cohort alone.

Table S6. Results for interactions with BMI in multivariable-adjusted cross-sectional associations in controls between baseline PFAS plasma concentrations and total cholesterol, LDL, HDL and triglycerides of two pooled Swedish cohorts, estimated using linear mixed effects models as well as in multivariable-adjusted prospective associations between baseline PFAS plasma concentrations and cardiovascular disease (CVD) risk of two pooled Swedish cohorts, estimated using conditional logistic regression – PFHpA and PFOA results are from 60YO cohort alone.

Table S7. Multivariable-adjusted prospective associations between baseline PFAS plasma concentrations and subsequent risk of cardiovascular disease (CVD), estimated in SMC-C and 60YO cohorts using conditional logistic regression – PFHpA and PFOA results are from 60YO cohort alone.

Table S8. Multivariable-adjusted prospective associations between baseline PFAS plasma concentrations and subsequent risk of myocardial infarction (MI), estimated in SMC-C and 60YO cohorts using conditional logistic regression – PFHpA and PFOA results are from 60YO cohort alone.

Table S9. Multivariable-adjusted prospective associations between baseline PFAS plasma concentrations and subsequent risk of stroke, estimated in SMC-C and 60YO cohorts using conditional logistic regression – PFHpA and PFOA results are from 60YO cohort alone.

Figure S1. Pairwise Spearman's rank correlations between different PFAS at baseline using both cohorts (SMC-C and 60YO), except for PFHpA and PFOA which were derived using the 60YO cohort alone. Abbreviations: **PFHxS**, perfluorohexane sulfonic acid; **PFHpA**, perfluoroheptanoic acid; **PFOS**, perfluorooctane sulfonate; **PFOA**, perfluorooctanoic acid; **PFNA**, perfluorononanoic acid; **PFDA**, perfluorodecanoic acid; **PFUnDA**, perfluoroundecanoic acid.

Figure S2. Multivariable-adjusted cross-sectional associations in controls of two Swedish pooled cohorts (SMC-C baseline: 2003-2009 and 60YO baseline: 1997-1999) between baseline PFAS plasma concentrations and a) LDL in pooled cohorts, estimated using linear mixed effects models stratified by BMI (lean: n=253, overweight: n=373) and b) apoB in the 60YO, estimated using a linear regression stratified by BMI (lean: n=105, overweight: n=200). PFHpA and PFOA are from 60YO cohort alone. Adjusted β -coefficients ($\pm 95\%$ CIs, mmol/L) of blood lipids are presented by 1-SD increment in natural log-transformed plasma PFAS concentrations (ng/mL). Models are adjusted for age, sex, sampling date, education, diabetes, hypertension, family history of CVD, smoking habits, physical activity and healthy diet score. Individual PFAS were standardized (rescaled with mean=0 and SD=1) and summed (Σ PFAS). PFHpA and PFOA which were derived using the 60YO cohort alone. Abbreviations: **PFOS**, perfluorooctane sulfonate; **PFNA**, perfluorononanoic acid; **PFDA**, perfluorodecanoic acid; **PFUnDA**, perfluoroundecanoic acid.

Appendix S1. Certificate quality control PFAS measurements (University of Erlangen-Nuremberg, Germany).

Appendix S2. Certificate quality control PFAS measurements (HBM4EU).